What are the similar drugs to erdafitinib? Comparative analysis of other similar targeted drugs

Erdafitinib is an FGFR inhibitor, mainly used to treat FGFR gene mutation-positive advanced urothelial carcinoma. It prevents the proliferation of cancer cells and tumor progression by inhibiting the activation of fibroblast growth factor receptor (FGFR). As a targeted therapy drug, erdafitinib's class of drugs includes other FGFR inhibitors and drugs that target important signaling pathways in cancer cells. The following are several common similar drugs and their comparative analysis:

1. Pemigatinib (Pemigatinib): Pemigatinib is an FGFR inhibitor, mainly used to treat FGFR2 gene mutation-positive cholangiocarcinoma. Unlike erdafitinib, the indications of pigatinib are mainly focused on cholangiocarcinoma, while erdafitinib is mainly used to treat urothelial cancer. Both are FGFR inhibitors that reduce the proliferation of cancer cells by inhibiting the activity of FGFR, but their targets are different. Pigatinib is more focused on the inhibition of FGFR2. There are also differences in the side effects and resistance mechanisms of the two. The side effects of pigatinib include abnormal liver function and retinopathy, while erdafitinib may cause problems such as rash, dry eyes, and hypercalcemia.

2. Ponatinib (Ponatinib): Ponatinib is a multi-target tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Unlike erdafitinib, the target of palpatinib is not limited to FGFR, but also includes multiple targets such as BCR-ABL and PDGFR. Although both involve the inhibition of targeted signaling pathways, palpatinib is more commonly used in the treatment of leukemia, while erdafitinib focuses on FGFR-mutated urothelial cancer. The side effects of the two are different. Common side effects of palpatinib include blood clots and heart problems, while the more common side effects of erdafitinib include eye discomfort, rash and gastrointestinal discomfort.

3. Famatinib (Fibrofenib):Famatinib is a FGFR1, 2, 3, 4inhibitors are also used to treat FGFR mutation-positive cancers, especially non-small cell lung cancer (NSCLC) and cholangiocarcinoma. Famatinib has a wider range of targets than erdafitinib, and its ability to inhibit FGFR4 is stronger. Compared with erdafitinib, famatinib has a wider clinical application and covers more types of cancers, including non-small cell lung cancer. Although both involve targeted therapy of FGFR mutations, the efficacy in different cancer types may be different.

Reference link:https://www.balversa.com/